Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

Summary

This study includes treating patients with atrial fibrillation (AF) with Dabigatran, an anti-coagulant for a period of one year to see if there are any significant changes in the degree of left atrial structural remodeling in these patients. The investigators hypothesize that there will be a significant decrease in the degree of left atrial structural remodeling (fibrosis) in AF patients treated with dabigatran.

Timeline

Start

2012-02

Primary completion

2013-12

Completion

2013-12

Drugs

Indications